AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00150098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced HIV risk reduction and HIV vaccine education
Study NCT03359135 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation
Description: Rehabilitation during 4 weeks
Study NCT03359135 — intervention group
Intervention type: DEVICE
Intervention: Compression Garment
Description: Rehabilitation associated to wearing CG during 4 weeks
Study NCT04319900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: favipiravir tablets+chloroquine phosphatetablets tablets
Description: Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).~Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.~Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug.
Study NCT04319900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir tablets
Description: Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
Study NCT04319900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.
Study NCT01208090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800
Description: ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Study NCT01208090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Study NCT01056445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: valsalva maneuver
Description: valsalva maneuver after carotid stenting
Study NCT02714114 — intervention group
Intervention type: OTHER
Intervention: First-void urine collection
Description: One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
Study NCT02714114 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccinations (CEV).
Study NCT03174210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: liquid oxygen device (LOD)
Description: This oxygen Supplementation is used in special order
Study NCT03174210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: portable oxygen concentrator (POC)
Description: This oxygen Supplementation is used in special order
Study NCT03903510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: Participants in the experimental group will receive an AppliedVR virtual reality headset during their cast removal.
Study NCT04107727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.
Study NCT04107727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.
Study NCT04107727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days.
Study NCT04107727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days.
Study NCT04107727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Idarubicin
Description: Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
Study NCT04107727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
Study NCT00492973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone acetate
Description: Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate
Study NCT00492973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active comparator
Description: bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline
Study NCT02984592 — intervention group
Intervention type: BEHAVIORAL
Intervention: physical exercise
Description: regular exercise programs in the previous 6 months.
Study NCT03244007 — intervention group
Intervention type: PROCEDURE
Intervention: Vitrectomy
Study NCT03029975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training Exercise
Description: Participants will undergo 10 weeks of progressive resistance exercise training while following their randomly assigned nutritional intervention.
Study NCT03029975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training Exercise
Description: Participants will undergo 10 weeks of progressive resistance exercise training while following their randomly assigned nutritional intervention.
Study NCT03029975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beef Protein Consumption
Description: Following each resistance training sessions, participants will consume either a 3oz or 6oz beef patty (corresponding to the randomly assigned nutritional intervention group). Participants will also be provided with beef protein powder and beef snack bars to help them achieve their assigned protein goals during the intervention period.
Study NCT03029975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beef Protein Consumption
Description: Following each resistance training sessions, participants will consume either a 3oz or 6oz beef patty (corresponding to the randomly assigned nutritional intervention group). Participants will also be provided with beef protein powder and beef snack bars to help them achieve their assigned protein goals during the intervention period.
Study NCT01703858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 113608 PIB
Description: powder for oral solution
Study NCT01703858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: conventional tablet formulation
Study NCT01703858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg STADA
Description: film-coated tablet
Study NCT00363038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petrolatum United States Pharmacopeia (USP)
Description: Topical formation applied to bruise twice daily for 2 weeks.
Study NCT00363038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K and retinol ointment
Description: Topical formation applied to bruise twice daily for 2 weeks.
Study NCT00363038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arnica ointment
Description: Topical formation applied to bruise twice daily for 2 weeks.
Study NCT00363038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K ointment
Description: Topical formation applied to bruise twice daily for 2 weeks.
Study NCT03474679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive 420 mg (3 \* 140 mg capsules) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
Study NCT01258959 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound detection of local anesthetics spread
Description: During the parabulbar injection the ultrasound operator experienced in ultrasound guided retrobulbar block will assess whether there is spread of local anaesthetic in the central cone just behind the sclera (yes or no). The anaesthesist performing the block will be blinded to the ultrasound visualized spread of local anaesthetic.
Study NCT02456246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLT-PET
Description: Positron emission tomography scan using the 18f-FLT (3'deoxy-3'-fluorothymidine) tracer
Study NCT01242644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pain pump containing ropivacaine
Description: 30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour
Study NCT01242644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: saline pain pump with injectable medication
Description: 30mL of ropivacaine(0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
Study NCT01242644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine, ketorolac , morphine sulfate
Description: 30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected
Study NCT00706030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Study NCT00625443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded (placebo)
Description: Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months
Study NCT00625443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label (Avatrombopag tablets)
Description: Dose 10 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months
Study NCT00625443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded (Avatrombopoag tablets)
Description: Dose: 2.5, 5, 10, or 20 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months
Study NCT04350970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal therapy
Description: All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The high flow nasal therapy was used during all exercise test.
Study NCT04350970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation
Description: All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The NIV was used during all exercise test.
Study NCT04350970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The control test was performed with no additional therapy.
Study NCT01544361 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
Study NCT01544361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7814, 1 MG/KG
Description: A single dose of MEDI7814, 1 mg/kg intravenous infusion over at least 60 minutes on Day 1.
Study NCT01544361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7814, 3 MG/KG
Description: A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
Study NCT01544361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7814, 10 MG/KG
Description: A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
Study NCT00706030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Study NCT00433407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT03851783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solar-powered oxygen
Description: Constant and reliable administration of oxygen, using solar panels to power an oxygen concentrator and deliver medical grade oxygen at 1-5L/min.
Study NCT02219139 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ESTA abutment Roxolid
Description: Enhanced Soft Tissue Attachment surface on Roxolid or machined surface on Roxolid abutment placement.
Study NCT00865215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride Extended Release Capsules 160 mg
Description: A: Experimental Subjects received Actavis formulated products under fasting conditions
Study NCT00865215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INDERAL® LA 160 mg Capsules, single dose
Description: B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
Study NCT05103865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (AAT)
Study NCT05103865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual treatment
Study NCT04315896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: hydroxychloroquine 400mg day for 10 days
Study NCT04315896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study NCT01544361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7814, 20 MG/KG
Description: A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
Study NCT02934347 — intervention group
Intervention type: PROCEDURE
Intervention: 25 degree back-up position
Description: To test whether a 25 degree back-up position improves laryngeal views and makes intubation easier compared to the standard horizontal position
Study NCT02208492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is a second-generation antiepileptic drug that has been approved for the treatment of epilepsy in both children and adults. This anticonvulsant works by binding to the synaptic vesicle protein 2A resulting in a possible effect on neurotransmitter release from presynaptic vesicles, while the exact mechanism of action is still unclear. In both adults and children, levetiracetam treatment in has a proven efficacy in both localization-related and generalized epilepsies. In contrast to first generation, levetiracetam reports less side effects of somnolence or lethargy, but behavioral adverse events, such as changed mood state, aggression, and irritability are noted, but only a few studies have reported such effects in a systemic fashion.
Study NCT02208492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carabamazepine
Description: Carbamazepine, a first-generation antiepileptic medication, stabilizes the inactivated state of voltage-gated sodium channels, making fewer of these channels available to subsequently open, which leaves the affected cells less excitable and less seizure prone. It is approved for both focal seizures and generalized tonic-clonic or combined seizures for adults and children.
Study NCT02404194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Training
Description: Targeted Cognitive Training is performed on the computer through Posit Science. Games are modern and engaging modifications of classic neuropsychological tests, such as set-shifting games modeled on the Wisconsin Card Sort Test, and cognitive control games modeled on Stroop-like interference tasks. Games will target two sets of skills: Targeted cognitive skills include: processing speed, memory, attention, flexibility/cognitive-control, and problem-solving. After 20 hours of training on these skills, participants will complete 20 hours of training on core social cognitive skills, including facial affect recognition, gaze direction perception, and face identity recognition, and theory of mind.
Study NCT02404194 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer Games
Description: The comparison intervention consists of 40 hours of commercially available and cognitively non-specific computer games. These computer games - such as checkers, solitaire, crossword puzzles - are entertaining and engaging but do not target specific neurocognitive skills.
Study NCT03548389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin to skin contact
Description: By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
Study NCT01308866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Share decision tool
Study NCT03460431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser 10,600nm
Description: fractional CO2 laser 10,600nm session, every month for 4 months
Study NCT03460431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd YAG laser1064 nm
Description: Nd YAG laser1064 nm laser session, every month for 4 months
Study NCT00783484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc +PF-03716539
Description: Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
Study NCT02801266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence informed birth control counseling
Description: Counselors underwent training on the use of 10 best practices for contraceptive counseling.
Study NCT01710137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Study NCT01710137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02668367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTA-C585 oral capsules
Description: BTA-C585; Multiple ascending doses from 100 mg to 600 mg
Study NCT02668367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BTA-C585 matching placebo
Description: Multiple ascending doses to match 100 mg to 600 mg BTA-C585 capsules
Study NCT04121676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2373
Description: An Anti-CD137 Monoclonal Antibody
Study NCT02715687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Will receive 30 days treatment with oral amniodarone of 200mg
Study NCT02715687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will receive 30 days treatment with oral placebo of 200mg
Study NCT01934569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771
Description: PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
Study NCT04121676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Anti-CTLA-4 Monoclonal Antibody
Study NCT04586985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-6058/placebo oral capsule(s)
Description: Subjects will receive FTX-6058 or matching placebo.
Study NCT04586985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-6058 - Two Dosing Periods
Description: Subjects will receive FTX-6058
Study NCT06773702 — intervention group
Intervention type: OTHER
Intervention: gastroenterology and otolaryngological evaluation
Description: * Gastroenterology evaluation: presence and intensity of esophageal symptoms of gastro esophageal reflux disease, high-resolution esophageal manometry, and 24-hour pH-impedancometry in the absence of PPI therapy.~* otolaryngological evaluation: presence and intensity of laryngopharyngeal reflux symptoms, laryngoscopy.
Study NCT04586985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-6058 / Midazolam Syrup
Description: Subjects will receive FTX-6058 and midazolam syrup
Study NCT01710137 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling
Study NCT01710137 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Study NCT00689117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT Gel
Description: Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks